Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
European Journal of Clinical Pharmacology|January 1, 1994
Differences in the bioavailability of dihydrotachysterol preparationsR Koytchev, R G Alken, M Vagaday, et al.Die Pharmazie|January 1, 1994
[Pharmacokinetics and biotransformation of 3-cyan-2-morpholino-5-(pyrid-4-yl)pyridine (AWD 122-14) in the rat]M Vagaday, U Kunter, D Labes, et al.Arzneimittel-Forschung|February 1, 1994
[Absolute bioavailability of chlorpromazine, promazine and promethazine]R Koytchev, R G Alken, V Kirkov, et al.Kidney International|January 5, 2000
Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetesT M Coimbra, U Janssen, H J Gröne, et al.Anticancer Research|December 29, 2000
Tumour microdissemination and survival in metastatic melanomaA J Schrader, M Probst-Kepper, J Grosse, et al.Melanoma Research|September 14, 2000
Molecular and prognostic classification of advanced melanoma: a multi-marker microcontamination assay of peripheral blood stem cellsA J Schrader, M Probst-Kepper, J Grosse, et al.The Journal of Clinical Investigation|October 8, 1999
VEGF(165) mediates glomerular endothelial repairT Ostendorf, U Kunter, F Eitner, et al.Journal of the National Cancer Institute|May 1, 1996
Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanomaU Kunter, J Buer, M Probst, et al.Journal of Neurological Surgery. Part A, Central European Neurosurgery|January 14, 2012
Prophylactic intravenous nimodipine treatment in skull base surgery: pharmacokinetic aspectsC Scheller, A-S Vogel, S Simmermacher, et al.Kidney International|October 5, 2007
CCN3 is a novel endogenous PDGF-regulated inhibitor of glomerular cell proliferationC R C van Roeyen, F Eitner, T Scholl, et al.Pageof 1